THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE

The Lancet

Volumn 333, Issue 8649, 1989, Pages 1215-1220

  Gent, Michael ^a   Donald Easton, J ^c   Hachinski, VladimirC ^e   Panak, Edouard ^g   Sicurella, Jane ^a   Blakely, JohnA ^b   Ellis, DavidJ ^d   Harbison, JohnW ^f   Roberts, RobinS ^a   Turpie, AlexanderG G ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c BROWN UNIVERSITY   (United States)

^d ROCHE BIOSCIENCE   (United States)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TICLOPIDINE;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOEMBOLISM;

AGED; CANADA; CAUSE OF DEATH; CEREBROVASCULAR DISORDERS; COHORT STUDIES; COMPARATIVE STUDY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PATIENT COMPLIANCE; PROGNOSIS; RANDOM ALLOCATION; RECURRENCE; SUPPORT, NON-U.S. GOV'T; TABLETS; THROMBOEMBOLISM; TICLOPIDINE; UNITED STATES;

EID: 0024411823     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(89)92327-1     Document Type: Article

References (34)

1. Survival and recurrence following stroke: The Framingham Study
2. Transient cerebral ischemia; pathogenesis, prognosis and management
3. Secondary prevention of vascular disease by prolonged anti-platelet therapy
4. A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke
5. Single studies and overview analyses: is aspirin of value in cerebral ischemia?
6. High dose acetylsalicylic add after cerebral infarction
7. The mechanisms of action of ticlopidine
8. Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications
9. Ticlopidine
10. Ticlopidine: a review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states
11. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke: design, organization and baseline results
12. Nonparametric estimation from incomplete observations
13. Evaluation of survival data and two new rank order statistics arising in its consideration
14. Regression models and life tables
15. Designs for group sequential tests
16. Controlled trial of aspirin in cerebral ischemia
17. Controlled trial of aspirin in cerebral ischemia II. Surgical group
18. A randomized trial of aspirin and sulfinpyrazone in threatened stroke
19. Aspirin in patients with cerebral ischemia and normal angiograms or non surgical lesions. Results of a double blind trial
20. Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks
21. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettairs. Resultats d'un essai therapeutique controle de 3 ans
22. A randomized trial of aspirin and sulfinpyrazone in patients with TIA
23. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia
24. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish Cooperative Study
25. Persantine aspirin trial in cerbral ischemia. Part II. Endpoint results
26. The UK-TIA aspirin trial; the interim results
27. The European stroke prevention study (ESPS); principal endpoints
28. Controlled trial of dipyndamole in cerebral vascular disease
29. Platelets, drugs and longevity in a geriatric population
30. A prospective trial of sulfinpyrazone and survival after thrombotic stroke. VIIth International Congress on Thrombosis and Haemostasis
31. Effect of drugs that suppress platelet surface interaction on incidence of amaurosis fugax and transient cerebral ischemia
32. The qualification and disqualification of patients and events in long-term cardiovascular clinical trials
33. Controversy in counting and attributing events in clinical trials